Butt JH, Docherty KF, Petrie MC, et al. - This prespecified subgroup analysis of a phase 3 randomized clinical trial was undertaken to determine dapagliflozin’s efficacy and safety vs that of placebo in men and women with heart failure (HF) with reduced ejection fraction (HFrEF) enrolled in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). Interventions included addition of once-daily 10 mg of dapagliflozin or placebo to guideline-recommended therapy. In DAPA-HF, 4744 patients underwent randomization, of whom 1109 were females (23.4%). As per findings, the observed decrease in the risk of worsening HF, cardiovascular death, and all-cause death after treatment with dapagliflozin was similar in men and women and also dapagliflozin improved symptoms, physical function, and health-related quality of life similarly in both genders, in this study population with HFrEF. Additionally, findings showed the safety as well as the good tolerability of dapagliflozin, regardless of gender.